|Bid||3.3500 x 1800|
|Ask||3.3600 x 900|
|Day's range||3.2613 - 3.4550|
|52-week range||3.2200 - 25.0550|
|Beta (5Y monthly)||3.41|
|PE ratio (TTM)||N/A|
|Earnings date||01 Aug 2022 - 05 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||16.50|
CAMBRIDGE, Mass., May 10, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present data from its ECOSPOR III trial of SER-109 at the Digestive Disease Week® (DDW) Annual Meeting, which is taking place May 21-24, 2022. SER-109 is an investigational oral microbiome therapeutic for the prevention of recurrent C. difficile infection (rCDI). With an oral and poster presentation, Seres will present data on how SER-109 restores the f
Market forces rained on the parade of Seres Therapeutics, Inc. ( NASDAQ:MCRB ) shareholders today, when the analysts...
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.93% and 79.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?